Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A new discussion of an mRNA cancer vaccine partnership between Moderna and Merck highlights the promise, and the remaining uncertainty, around vaccines designed to help the immune system recognize cancer.
THE APEX TIMES
THE APEX TIMES
A recent market commentary highlights a split between price performance and Wall Street sentiment for HCA Healthcare, with analysts described as still moderately optimistic about the stock’s potential.
THE APEX TIMES
A recent market report says UnitedHealth is aiming for better margins in Medicare Advantage by tightening benefits, improving pricing discipline, and putting more emphasis on cost controls rather than simply adding more members.
THE APEX TIMES
The company’s update to its robotic bronchoscopy platform cleared the FDA through the 510(k) pathway, adding AI-assisted planning and navigation plus upgrades aimed at improving imaging used during lung procedure guidance.
THE APEX TIMES
With shares recently trading around $1,280, investors are again asking whether Eli Lilly could be the next major U.S. company to split its stock to keep the price accessible.
THE APEX TIMES
Across biopharma, shareholder activism and platform competition are colliding. A new push by Kaos Capital targets Capricor’s board and strategy, while Eli Lilly outlines continued focus on vaccine development. In parallel, Bristol Myers is advancing work described as an AI-powered discovery engine.
THE APEX TIMES
Revere Asset Management’s Don Vandenbord says AI-focused capital that starts in software and platforms could broaden into biotech, with Moderna’s stock becoming one of the familiar places to watch.
THE APEX TIMES
Moderna shares jumped and BioNTech rose as traders revisited the same clinical catalyst across multiple sessions, with options activity suggesting the volatility may not be finished.
THE APEX TIMES
Moderna shares ended the week higher after a session marked by sharp swings, while crypto-related stocks reportedly extended a recent rally in a broader risk-on market tone.
